Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR

University of Birmingham, Birmingham, England, United Kingdom
Journal of Hepatology (Impact Factor: 11.34). 07/2004; 40(6):986-92. DOI: 10.1016/j.jhep.2004.02.009
Source: PubMed


Lamivudine is an antiviral drug that is used to treat hepatitis B virus (HBV) infection. Long-term therapy does not completely suppress viral replication, and resistant mutants emerge. Resistance is mediated by changes in the tyrosine-methionine-apartate-aspartate (YMDD) motif in the catalytic site of the HBV polymerase gene. We describe a method to detect and quantify mutant viral populations using amplification refractory mutation system (ARMS) PCR.
We developed a real-time ARMS-PCR to detect point mutations in the polymerase gene. Using real-time PCR (LightCycler) with a ResonSense probe, PCRs were performed using clones of the HBV polymerase gene containing the different YMDD mutations. Dilution series of the templates were made and tested against each of the primer pairs. This method was applied to quantify mutant virus in patient serum samples.
As little as 0.01% mutant DNA in 10(5)-10(9) copies wild-type DNA were detected. The method is more sensitive than amplicon sequencing, which is the current method of mutant determination in the YMDD motif.
This study demonstrates a rapid, highly sensitive and reproducible method of quantifying mutant HBV virus in lamivudine treated patients. It can be used to monitor patients before and during lamivudine therapy.

Download full-text


Available from: Chong-Gee Teo, Jun 18, 2015
  • Source
    • "Briefly, discrimination between wild type and mutant with a single base pair mismatch is made possible using a primer-template mismatch at the 3' end of the primer, which significantly compromises polymerase efficiency in amplifying the wild type strain. Primers and probes for rtM204V/I were described previously and the assay can detect up to 0.1% variants for a total viral load of 105 copies/mL [13]. We designed and evaluated a specific reverse primer (5'-ATCTTTTTGTTTTGTTAGGGG-3') for the detection of the rtN236T-mutation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sequential monotherapies of nucleotide analogs used in chronic hepatitis B treatment can lead to the selection of a resistance mutation to each antiviral drug. A patient with chronic hepatitis B was successively treated with lamivudine monotherapy, lamivudine-adefovir dual therapy, adefovir monotherapy and again with an adefovir-lamivudine dual therapy. Lamivudine-associated mutations (rtL180M and rtM204V/I) followed by adefovir-associated mutations (rtN236T and rtA181V) emerged during the two monotherapy regimens. Despite the presence of rtM204V/I, rtA181V, and rtN236T mutations at the beginning of the second dual therapy, sustained biochemical and virological responses have been observed thus far after 23 months. This case illustrates that rtM204V/I, rtA181V, and rtN236T resistance mutations can coexist in a patient but do not preclude the recycling of lamivudine and adefovir in combination therapy, when no other therapeutic choices are available.
    Comparative Hepatology 02/2008; 7(1):3. DOI:10.1186/1476-5926-7-3 · 1.88 Impact Factor
  • Source
    • "Moreover, for unequivocal detection of lamivudine resistance, the variant subpopulation may have to comprise at least 5% to 10% of the total 33. Another test that employs mixed hybridization-sequencing-PCR (“minisequencing”) technology involves the extension of multiple oligonucleotide primers with fluorescent ddNTPs by means of a DNA polymerase 34. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Serological markers are key elements in diagnosing acute hepatitis B virus (HBV) infection and determining its possible evolution towards chronicity. Once treatment of chronic HBV is initiated with approved anti-hepadnaviral agents, such as lamivudine, interferon-alpha, or adefovir dipivoxil, the measurement of HBV DNA in serum can not only help monitor treatment efficacy but also indicates breakthrough infection should drug resistance emerge. Advances in the molecular diagnosis of drug resistance using highly sensitive methodologies such as DNA hybridization assays can further pinpoint the type of mutation responsible and, more importantly, detect upcoming viral resistance at an early stage when the variant represents only a minor fraction of the total viral population. Such new tools are especially relevant for patients at high risk for disease progression or acute exacerbation. Recent diagnostic developments including HBV genotyping and precore/core promoter assays that could well play important future roles in HBV patient management are also reviewed.
    International journal of medical sciences 02/2005; 2(1):8-16. DOI:10.7150/ijms.2.8 · 2.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIM: To investigate the mutation of hepatitis B virus (HBV) with the treated with interferon (IFN)-α 2b. METHODS: Different doses of IFN-α 2b were added to the HepG2.2.15 cell culture. The α -fetoprotein (AFP) in the supernatant was assayed by Western blot. HBV DNA was isolated from the culture medium. HBV C gene amplified by PCR was cloned by T-A cloning into pGEM-T easy vector. The recombinatant was sequenced with T7/SP6 primer, and analyzed by DNA software. RESULTS: AFP in the culture medium was detected, which was not reduced after IFN-α treatment. There were two sub- types of preC/C gene in the control group. The homogene- ity was 93%, with 10 amino acids different, 6 of which were of identical characteristics. The same subtypes were found in the experiment group. The proportion of the dominant strain gene was altered in the high dose IFN group. There were 4 insertion/ deletion mutations in the high dose IFN experiment group, which resulted in reading frame shift. The mean homogeneity was more than 97%.
    World Chinese Journal of Digestology 03/2005; 13(6).
Show more